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Abstract Safe and effective medication for attention deficit
hyperactivity disorder (ADHD) is available and recommended
as first-line treatment for the core symptoms of inattention,
overactivity and impulsiveness. Despite impaired functioning
during adolescence, many discontinue medication treatment.
For children, healthcare decisions are usually made by the
parent; older youth make their own decisions. Beliefs and
attitudes may differ widely. Some families understand that
ADHD is a neurobiological condition and accept that medica-
tion is indicated, for others, such treatment is unacceptable.
Converging evidence describes negative perceptions of the
burden associated with medication use as well as con-
cerns about potential short and long term adverse ef-
fects. Indeed experiences of adverse effects are a
frequent explanation for discontinuation among youth.
Ways to improve shared decision making among practi-
tioners, parents and youth, and to monitor effectiveness,
safety and new onset of concurrent difficulties are likely
to optimize outcomes.
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Introduction
In the following chapter we summarize patterns of medica-
tion use for ADHD and describe what is known about
factors influencing adherence to ADHD medication.
Choices about using medication are complex, with more
recent work focusing on beliefs and attitudes that shape
patient preferences. In addition, effectiveness and adverse
effects are important factors and we review what is known
about the differences among commonly used ADHD med-
ications. We end with a discussion of the challenges and
related opportunities facing clinicians who work with young
people with ADHD. The field remains under-researched
with much more to learn about how to assist greater
numbers of young people with ADHD to maximize
their potential.
Background
Attention deficit hyperactivity disorder (ADHD) is a neuro-
biological disorder, characterized by symptoms of inatten-
tion, overactivity and impulsivity [1]. ADHD is estimated to
affect 5 % children worldwide and boys are classified with
ADHD approximately twice as frequently as girls and pri-
mary school age children approximately twice as frequently
as adolescents [1].
Throughout childhood and adolescence, clinically sig-
nificant ADHD is often associated with concurrent op-
positional and aggressive behaviors, also anxiety, low
self-esteem, and learning disabilities [1]. While ADHD
begins before children enter school, it is most common-
ly identified and treated in primary school, ages 7 to
9 years old [1]. In the preschool age group, ADHD is
characterized not only by impairment in attention span,
excessive impulsivity, but also is frequently accompanied by
additional disruptive behavior symptoms, including severe
temper tantrums, demanding, uncooperative behavior and
aggressiveness [1]. While levels of symptoms decrease
with age, the majority of children with ADHD continue
to show impairment relative to same-age peers throughout
adolescence and into adulthood [1].
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Many studies have documented increased risk for youth
with ADHD for leaving school early, increased contact with
the law, early onset substance use, and associated conduct,
mood and anxiety disorders [1]. More recently studies have
also documented higher risk for dangerous driving, suicidal
behavior, problem gambling, eating disorders and early parent-
hood [2–6]. Over the years, `ADHD interventions have largely
targeted children in the primary school age group`, with the
hope and expectation that early treatment will diminish such
poor psychosocial and mental health outcomes in adolescence.
However few studies exist that examine long-term effective-
ness of interventions with follow up beyond 12 months [1].
Most of those available evaluate use of medications, primarily
psychostimulants [1]. Overall outcomes in adolescence remain
less than optimal with many youth continuing to show func-
tional impairment even where stimulant medications have been
combined with intensive behavioral interventions [7]. A few
studies suggest that continued medication use during adoles-
cence improves academic outcomes and postpones substance
initiation [8–10]. However it is difficult to distinguish between
medication treatment and other family, socioeconomic and
psychosocial factors that may support increased use of
healthcare services. Interestingly, a recent population based
study from Sweden among persons older than 16 years, shows
that periods of medication use are associated with diminished
contact with the law, and non-use is associated with a return to
illegal activities [11]. This study demonstrates effectiveness of
medication interventions for an important functional outcome,
but also underlines that the benefits of medication are not
maintained when treatment is discontinued. Therefore one
important reason for suboptimal outcomes in adolescence
may be poor medication adherence [12].
There are primarily two types of pharmacological agent with
proven efficacy over 12 months for ADHD: psychostimulants,
(e.g., methylphenidate, or amphetamine derivatives such as
dextroamphetamine and mixed amphetamine salts) and a
norepinephrine reuptake inhibitor, atomoxetine [1].
Psychostimulants continue to provide control of ADHD symp-
toms and are generally well tolerated for months to years at a
time, although adverse effects, most commonly decreased ap-
petite, sleep disturbances, headaches and stomachaches, may
continue to be present [13]. Methylphenidate improved ADHD
symptoms and overall functioning alone or in combination with
psychosocial/behavioral interventions for 14 months and up to
Table 1 Factors associated with ADHD medication adherence
Factor Predictors of increased adherence Predictors of decreased adherence
Parent/family Two-parent families* [12] Older parents [12]
Higher socioeconomic status* [12] Increased parent-child conflict [1, 40]
Belief that medication is safe [33••] Belief that symptoms are not a disorder [12, 38]
Belief that ADHD is neuro-biological disorder [35] Distrust of the medical system [12, 38]
Stigma [12, 38]
Burden of medication regimen [40]
Concerns about medication safety [33••]
Healthcare system/ professional Insurance coverage [46] Cost of medication [46]
Specialty care [28] Lack of providers in the community [24, 46]
Prior history of medication treatment [12, 38]
Good relationship with doctor [38]
Child Caucasian racial background [20, 21] Older child age at diagnosis [40]
Increased symptom severity [12, 38] Family history of ADHD [1]
Combined subtype [1] Severe behavior problems at home [12, 40]
Comorbidities present (oppositional defiant disorder,
depression, social skills, anxiety, developmental delay,
learning disabilities) [12, 38]
Child unwilling [12, 40]
Adolescent Academic benefits [33••] Negative attitudes toward medication [33••]
Few adverse effects [33••, 41] Stigma [12, 33••, 42, 44••]
Concerns about treatment dependence [16]
Experience of social withdrawal [16, 42]
Medication Long-acting formulations [20, 25, 26] Medication ineffectiveness [1]
Adverse effects (physiological/psychological) [1, 42]
Multiple daily doses [40]
Difficulties adjusting the dose regimen [52]
* The evidence regarding direction of influence is not consistent
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24 months [7, 14]. The benefits and safety of methylphenidate
for symptom control and general functioning are most clearly
documented, for boys, ages 7 to 9 years at initiation, with
ADHD combined type [1]. However the benefits of
psychostimulants wear off when the medication is not taken
as the pharmacological half life is 3 to 5 hours in immediate
release medication [15]. Best practice guidelines recommend
that for full benefit both in school and at home, children with
ADHD should use these agents all day every day [15]. Children
who use psychostimulants, often continue treatment for three
years or more, although many discontinue use once they reach
adolescence [16, 17].
Patterns of Medication Use
Rates of clinical identification and medication treatment for
ADHD have increased over time from the early 1990s to
2005 or later [1]. Rates of medication use have increased
due to increased duration of use as well as increased use
among girls, preschool children, adolescents and adults [1].
Rates vary by geography, provider type and patient charac-
teristics as well as formulation of pharmacological agent.
Diagnosis and treatment is more common in the United
States than elsewhere world-wide, with approximately 1/3
of children and youth given a diagnosis of ADHD receiving
consistent treatment within the past year [18]. More pre-
scriptions, primarily pscyhostimulants, are given to patients
in the south and midwest regions of the United States
compared with the northeast [19]. Within the United States,
Caucasian children and those from higher income groups
are more likely to receive prescriptions and to use medica-
tion consistently than children and youth from minority
background [20, 21]. The most common age to begin med-
ication is between 5 and 9 years, more among boys than
girls [22]. One quarter to one third of patients receive a
single prescription [23, 24]. Treatment often is short-term
or intermittent, with one half to two thirds discontinuing
within one year [22, 23]. Teenagers are less likely to con-
tinue taking psychostimulants relative to younger children.
Once-daily extended release preparations improve the dura-
tion of stimulant use compared with immediate-release
agents [20, 25, 26].
Information is available about differences between pro-
vider type and subsequent prescribing patterns. Specialists’
practice patterns are different from those of primary care
physicians. Children diagnosed by psychiatrists are less
likely to receive a prescription within the initial six months
after diagnosis than those identified by primary care physi-
cians, even after adjustment for comorbid conditions [27].
Psychiatrists are more likely to provide titration of stimulant
doses with a lower initial dose, a higher maximal dose, and
three or more visits in the first 90 days, suggesting increased
monitoring [28]. Presence of comorbid disorders, especially
bipolar disorder, schizophrenia, or autism decreased the use
of ADHD drug use, but increased the use of other categories
of psychotropics, prescribed primarily by psychiatrists and
neurologists [27]. The techniques for medication initiation
used by specialists may be one reason that specialist care
leads to increased duration of use over time [29]. While
efficacy and safety of pharmacological agent are important
for continued use, the high-rate of non-refill following initial
prescription, as well as the variability by geography, provid-
er characteristics and the child’s age, ethnicity, and socio-
economic status suggests a nuanced approach to medication
adherence is warranted.
Patterns of continued medication use for ADHD vary
considerably, depending on sample characteristics and
method of measurement [12]. In community samples using
prescription databases, such as those described in the pre-
ceding paragraph, the mean time to discontinuation ranges
from 3 to 5 months, however, when single prescriptions are
removed, duration of use is considerably longer [17, 29, 30].
Cohort studies following participants enrolled in industry
sponsored trials document low rates of discontinuation due
to adverse effects, 12 % over 12 months on OROS methyl-
phenidate, 15- 21 % over 24 months on mixed amphetamine
salts, 11 % discontinued atomoxetine over more than 2 years
[1]. Consistent use was documented for 86 % of participants
at 12 months in a cohort study examining effectiveness of
OROS methylphenidate [31]. In general, estimates from
surveys and clinical samples suggest that 36-68 % of chil-
dren consistently use ADHD medications once initiated
[12]; consistent use declines over time from approximately
50 % at 2 years to 36 % at 5 years [13]. Fluctuations in use
are common; some children use medications regularly,
others discontinue, and still others stop and restart medica-
tions, sometimes more than once [13, 17].
Alongside the multiple patterns of ongoing medication
use, there often are multiple changes in dose and formula-
tion [17]. While treatment guidelines may encourage daily
use, parent interviews and self report surveys and cohort
studies suggest that up to 40 % of families prefer to target
behavior and learning at school and do not use medications
on weekends and during school vacations [12].
Medication Adherence
Empirically based models of health behavior offer the op-
portunity to examine social, cognitive, and experiencial
factors that influence medication adherence, cognitive be-
havioral models such as the health beliefs model take into
account characteristics of the specific disorder, patient be-
liefs and attitudes, and the efficacy and safety profile of the
medication, while a model such as the trans-theoretical
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model of change, describes the importance of experience
and associated changes in attitude over time [12]. While the
concept of treatment adherence has evolved in the past
20 years, it remains poorly operationalized and measured,
leading to a variety of interpretations by patients and pro-
viders [32•]. For young children with ADHD, healthcare
decisions are usually made by the parent and therefore the
parent’s perceptions and experiences are of central impor-
tance. However, parents often incorporate their understand-
ing of their child’s experiences [12].
In general, medication adherence connotes the child’s
and parent’s participation and engagement in using a med-
ication regimen believed to be beneficial by both the family
and the clinician who prescribes. The therapeutic partner-
ship maintained by ongoing patient-provider transactions
over time is essential for long-term adherence [32•]. For a
chronic condition such as ADHD, where successful out-
comes are more likely to occur with continued medication
use, challenges can arise with development as the young
person becomes an adolescent. Ideally the patient-provider
relationship also undergoes adjustments as the family trans-
fers healthcare decision-making from the parent to the
youth. However, adolescents are less willing to use medica-
tions for ADHD than are their parents [33••].
Factors That Influence Use of ADHD Medications
Generally speaking we can organize factors that are associated
with use of medication for ADHD into parent or family
characteristics, child characteristics, practitioner or health sys-
tem factors and medication-related factors (Table 1). Parent
beliefs about ADHD and attitudes toward treatment are sig-
nificant determinants of initiation [34]. For example those
parents who view the child’s difficulties as a medical disorder
that requires a biological intervention will agree with using
medication and encourage long term use [35]. Many however
prefer implementing behavioral strategies and other non-
medication strategies, such as dietary changes, exercise or
counseling [36, 37]. Families are more accepting of a trial of
stimulants when the diagnostic process has been thorough,
and included comprehensive psychological testing [36]. Some
parents feel that medication is unacceptable as treatment of
ADHD behaviors, and do not choose to use it for their child
[35]. Many parents have mixed feelings about starting medi-
cation, and often weigh concerns about adverse effects and
social disapproval against potential behavioral and academic
benefits [12, 38]. Increased knowledge about ADHD, and
associated attitudes that using medication is safe, effective
and socially acceptable increases willingness to use medica-
tion [33••]. However while knowledge may increase willing-
ness to try medication treatment, it is not clearly associated
with long term use [39].
Child characteristics that increase long term use of med-
ication are younger age when starting, more severe ADHD
symptoms, additional learning and behavior conditions, and
past experiences that medication is effective with few ad-
verse effects [12, 38]. In general children are less likely to
use medication when there are severe behavior problems at
home and the child is unwilling [12, 40]. Many children and
youth on medication do recognize benefits for improved
schoolwork and peer relationships [41–43]. Among adoles-
cents, the belief that medication is effective, in combination
with few experiences of adverse effects, increases willing-
ness to use medication [33••]. The young person’s evalua-
tion of how peers perceive them is very important. Some
youth feel ostracized socially due to ADHD behaviors and
therefore find taking medications helpful while others may
avoid treatment because of fears medication use will create
stigma [33••, 42, 44••]. University-aged young people with
ADHD described greater medication use when they made
the treatment decision themselves, often with the goal to
increase academic success [16]. Not surprisingly, as adoles-
cents mature, their ADHD symptoms become less obvious,
and their priorities change, patterns of medication use for
their ADHD symptoms are likely to change.
Parents describe that a good relationship with their
healthcare provider helped in the decision of starting treat-
ment in their children [38]. Those who trust their health care
provider and in general trust the health care system are more
likely to accept ADHD medication treatment [35]. Parents
and pediatricians have a similar, but not identical, under-
standing of what ADHD is, and the treatment priorities [45].
Families often consult with friends and relatives about the
advice doctors provide; where these informal consultations
concur with the provider’s advice to use medication, it is
more likely to happen [45]. Barriers to ongoing medication
use include the cost of prescriptions, while limited insurance
coverage and taking time off work can interfere with ongo-
ing monitoring and care [46]. Pediatricians note that provid-
ing care for children with special needs can be time-
consuming, with additional phone calls to schools and men-
tal health professionals outside of usual office hours [47].
The physician’s ability to clarify treatment preferences, dis-
cuss available options and maintain a treatment alliance with
the family is crucial to success.
Medication Effects
The most important medication factors influencing adher-
ence are effectiveness and tolerability. Ease of use, simpli-
fied dose regimen, and cost are also important [33••]. The
range of formulations for psychostimulants has burgeoned
over the last decade, especially in the United States com-
pared with other jurisdictions. A recent review of ADHD
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treatment studies examined ADHD medication use greater
than 12 months, and found studies of four psychostimulant
preparations (methylphenidate immediate release, amphet-
amine, OROS methylphenidate, and mixed amphetamine
salts) and a discontinuation trial evaluating atomoxetine [1].
While best evidence suggests that psychostimulants prepara-
tions are all efficacious compared to placebo, very few head-
to-head trials among stimulant preparations have been done.
However, the once daily formulation of OROS methylpheni-
date is more likely to be taken consistently than immediate
release methylphenidate which requires multiple doses daily
for efficacy [25, 26]. While the psychostimulants and
atomoxetine both reduce ADHD symptoms, and improve
social and academic functioning in placebo controlled
trials, not all children benefit equally well. Another
comparison of two agents examined OROS methylphe-
nidate and atomoxetine over several weeks, with the
conclusion that OROS methylphenidate is more effica-
cious for core ADHD symptoms [48].
Overall a substantial proportion of treatment discontinuation
in the first few months is due to adverse effects of medication
[1]. While families often may tolerate some adverse effects
over months to years, such as decreased appetite or mild
insomnia, other symptoms such as stomach aches, or head-
aches may be less tolerable [13]. A long-term comparison of
dextroamphetamine with methylphenidate formulations, sug-
gests dextroamphetamine agents are less well tolerated by girls
than boys [17]. In particular, psychological side effect such as
mood changes, irritability, depression and subdued personality
are frequent reasons for discontinuation [43]. Increased mood-
iness and irritability appears to be more common among pre-
school children than older ones [49]. Other reasons for
changing or discontinuing medications are slowing of the
child’s growth, development of tics, rashes and other concerns
the young person or family attribute to the medication. Psy-
chotic symptoms, are estimated to occur ADHDmedications at
a rate of 1.5 events / 100 person years [50] and suicidal ideation
is estimated to occur 5/1357 (0.37 %) in pediatric patients
taking atomoxetine [51].
The most frequently cited reasons for discontinuing med-
ication are the family’s experience that the medications are
not effective or the child is experiencing intolerable adverse
effects. The clinician should help the family have realistic
expectations for how ADHD medication can help, and pro-
vide frequent monitoring in the initial stages to address
emerging adverse effects, as two important methods to
improve medication adherence [52].
Challenges and Opportunities
The primary reason to examine ADHD medication adher-
ence is to provide the best care possible for children and
youth with ADHD so that long-term mental health, psycho-
social, and economic outcomes are optimized. However
despite extensive examination, solid evidence that medica-
tion interventions provide lasting long-term benefits remains
elusive. This conundrum is now being addressed using
large-scale population-based administrative databases,
linking data about prescription renewal rates with health
care and educational services information. Using complex
statistical methods, these studies show promise for describ-
ing community patterns of health care use and associated
outcomes. On the other hand, the specifics of individual
child characteristics, including clinical diagnosis, interper-
sonal relationships of families and providers, and co-
interventions received are rarely captured, offering little
practical guidance to front-line practitioners. The details
required to inform day-to-day practice require alternative
research methods. For example, studies using mixed quali-
tative and quantitative methods have begun to answer com-
plex questions about treatment adherence relevant for front
line practitioners. Converging evidence from multiple sam-
ples offers surprisingly similar descriptions of parent atti-
tudes and beliefs about childhood ADHD and its treatment
with medication. Indeed, one very important challenge for
physicians arising from this body of evidence is to acknowl-
edge the limitations of medication as a sole treatment for
ADHD. Parents, even those who rely on medication to assist
their children, identify areas of burden, have ongoing con-
cerns associated with its use, and articulate the need to
investigate additional ways to help their child reach their
full potential.
Another significant challenge to current practice is to
include children as active participants in treatment deci-
sions. This is not only good ethical practice but also the
best way to engage them in treatment. The opinions and
preferences of children and youth about their ADHD treat-
ment are not yet widely described, but progress is being
made. Young children certainly have less involvement in
their treatment decisions than adolescents, but when they are
unwilling to take medication, their parents experience the
burden of conflict and in turn, medication is likely to be
discontinued. Developing a thorough understanding of
young people’s concerns about their mental health treat-
ment, identifying and responding to their priorities and
addressing their concerns is important for optimizing out-
comes. Over time inattention and overactivity may become
less of a focus for intervention and other issues may emerge
as more significant. Maintaining the treatment alliance re-
mains key as medication use may once again become a
useful option at a later point in time.
When thinking about the long-term course of mental
health interventions for a young person with ADHD, it can
be important to recognize that early ADHD symptoms are a
risk marker for concurrent and subsequent difficulties. The
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literature about combining interventions with medication for
optimized outcomes remains sparse. The ini t ial
psychoeducation about what is ADHD and options for treat-
ment is a crucial first step in providing care, but one that is
not yet standardized. The process of seeking help for the
behavior and learning problems associated with ADHD is
complex and families often depend on informal as well as
formal sources of information within their community.
Therefore examining the best content to provide and the
best ways to communicate it remains important. Widely
disseminated, accurate general knowledge about ADHD
may also diminish stigma and misconceptions about poten-
tial long-term consequences of medication. The general
need for such mental health literacy extends to educators
as well as health care workers and to other trusted persons to
whom parents and youth go for answers.
Primary care practitioners play an important role as educa-
tors and gatekeepers in the process of identification and treat-
ment of ADHD. ADHD medication treatment needs to be
initiated in a way that encourages adherence and ongoing
monitoring should be provided to maximize benefit and min-
imize adverse effects. As technology is integrated into the
provision of healthcare services in general, it will also become
useful for those with ADHD. Prior to technical development
however, development and evaluation of standardized
methods will be required. These may include decision aids
to assist in informing parents and youth about options and
enhance shared decision making, and monitoring algorithms
with reminders to collect key information, address psycholog-
ical as well as physiological adverse effects and evaluate for
potential emergent concurrent disorders. Pharmacies already
use automated prescription renewal systems and these could
be adapted for daily use by the parent or by the young person.
Experiences of adverse effects remain a significant and
frequent reason for discontinuation of medications. As in
other areas where personalized medicine is under discus-
sion, there may be genetic biomarkers on the horizon to
assist in identifying which agents are likely to be most
effective and easier to tolerate for individual persons. In-
creased understanding about how the brain changes with
development and with prolonged treatment will bring new
knowledge about how to ensure brain health over many
years. Such information may also inform the most effective
way to use ADHD medications.
Conclusion
Medication is a key component of evidence-based care for
children with ADHD, and patterns of treatment adherence are
complex. Despite the fact that many young people show im-
paired functioning well into adolescence, many who begin
medication treatment either stop and start medications over
several years or discontinue use altogether. Explanations for
poor adherence to ADHDmedication treatment include patient
perceptions expressing many negative responses to the recom-
mendation of medication use. In addition, the healthcare pro-
vider often is working with more than one person in the family
who contributes to decisions. Not infrequently, patients and
families perceive less than optimum effectiveness and toler-
ance of adverse effects, both of which lead to discontinuation.
In this context, the clinician’s ability to maintain a positive
working alliance is crucial. Also important is monitoring for
concurrent or emergent difficulties; these problems may be-
come the priority rather than the ADHD symptoms, perhaps
requiring alternative or additional interventions. As we learn
more about brain health and development, additional ways to
help young people care for themselves will emerge; we may
see an increased focus on sleep hygiene, stress management,
diet and exercise, factors known to support positive mental
health. Overall increased awareness of the need for shared
decision making, with the young person as well as the parents
and enhancedmonitoring will remain key to enhancing ADHD
medication adherence and optimizing long-term outcomes.
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